期刊文献+

肾癌患者血清VEGF的水平及其与临床病理分期的关系 被引量:7

Renal Cell Carcinoma: Relationship between Level of Vascular Endothelial Growth Factor in Serum of Patients and Clinical Pathological Stage
原文传递
导出
摘要 目的:探讨肾癌患者血清血管内皮生长因子(VEGF)的水平及其与临床病理分期的关系。方法:选择2013年1月至2015年1月在我院行手术治疗的肾癌患者56例为观察组,选择同期在我院进行健康体检的正常成人50例作为对照,所有患者的诊断均经病理切片证实,对所有研究对象,采集其清晨空腹静脉血,用酶联免疫吸附法(ELISA)检测血清中的VEGF和VEGF受体-1(VEGFR-1)。结果:观察组血清中VEGF和VEGFR-1的浓度分别为(132.75±68.31)ng/mL和(33.76±15.39)ng/mL,均显著高于对照组,差异有统计学差异(均P<0.05);不同分期患者血清中VEGF和VEGFR-1浓度差异有统计学意义(均P<0.05),病理分期增加,VEGF与VEGFR-1的浓度增加,VEGF与VEGFR-1呈正相关(r=0.625,P<0.05)。结论:血清VEGF水平可用于诊断RCC,且对于预判RCC的病例分期具有重要价值。 Objective: To explore the relationship between level of vascular endothelial growth factor(VEGF) in serum of patients with renal cell carcinoma(RCC) and clinical pathological stage. Methods: A total of 56 patients with renal cell carcinoma, who underwent operation in Yunnan first people's Hospital from January 2013 to January 2015 were chosen as observation group; 50 cases of normal adults participated in health examination in the same period in the hospital, as control group. All the patients were confirmed by pathological biopsy. Early morning fasting venous blood of the research subjects were drawn, and the levels of VEGF and VEGFR-1 in the sera of the subjects were detected by ELISA. Results: The levels of VEGF and VEGFR-1 in the serum of patients with RCC were 132.75 ±68.31)ng/m L and(33.76±15.39)ng/m L respectively, which were significantly higher than the control group, with significant differences(P〈0.05). There were significantly statistical difference in VEGF and VEGFR-1 concentrations in the serum of patients with different stages(P〈0.05). VEGF was positively correlated with VEGFR-1(r=0.625, P〈0.05). Conclusion: The level of VEGF can be used as the diagnosis of RCC, which has an important value in staging of RCC.
出处 《现代生物医学进展》 CAS 2016年第21期4065-4067,共3页 Progress in Modern Biomedicine
基金 云南省卫生科技计划项目(2014NS265)
关键词 肾细胞癌 血管内皮生长因子 血管内皮生长因子受体 Renal cell carcinoma Vascular endothelial growth factor Vascular endothelial growth factor receptor
  • 相关文献

参考文献20

  • 1Zhi WI, Kim JJ. An update on current management of advanced renal cell cancer, biomarkers,and future directions [J]. Ann Cancer Res, 2014, 1(2): 1-10.
  • 2Song SH, Jeong IG, You D, et al. VEGF/VEGFR2 and PDGF-B/ PDGFR-13 expression in non-metastatic renal cell carcinoma: a retro- spective study in 1,091 consecutive patients[J]. Int J Clin Exp Pathol, 2014, 7(11): 7681-7689.
  • 3Czamecka AM, Kukwa W, Komakiewicz A, et al. Clinical and molec- ular prognostic and predictive biomarkers in clear cell renal cell can- cer[J]. Future Oncol, 2014, 10(15): 2493-2508.
  • 4Inglis D J, Lavranos TC, Beaumont DM, et al. The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and roTOR inhi- bitors in renal and breast cancer Ill. Cancer Biol Ther, 2014, 15(11): 1552-1560.
  • 5Van der Mijn JC, Mier JW, Broxterman I4d, et al. Predictive biomark- ers in renal cell cancer: insights in drug resistance mechanisms [J]. Drug Resist Updat, 2014, 17(4-6): 77-88.
  • 6Izzedine H, Massard C, Spano JP, et al. VEGF signalling inJ~ibifion-in- duced proteinuria: Mechanisms, significance and management[J]. Eur J Cancer, 2010, 46(2): 439-448.
  • 7Sharma SG, Nanda S, Longo S. Anti-angiogenic therapy in renal cell carcinoma[J]. Recent Pat Anticancer Drug Discov, 2010, 5( 1): 77-83.
  • 8Du K, Gong HY, Gong ZM. Influence of serum VEGF levels on thera- peutic outcome and diagnosis/prognostic value in patients with cervi- cal cancer[J]. Asian Pac J Cancer Prev, 2014, 15(20): 8793-8796.
  • 9Hejnold M, Dyduch G, Bia/as M, et al. Selected features of conventional renal cell carcinomas coexpressing P53 and MDM2[J]. Pol J Pathol, 2014, 65(2): 113-119.
  • 10Yang YQ, Chen J. Predictive role of vascular endothelial growth fac- tor polymorphisms in the survival of renal cell carcinoma patients EJ]. Genet Mol Res, 2014, 13(3): 5011-5017.

同被引文献51

引证文献7

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部